Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lux

Showing results (211-220 of 233) with videos related to

Pageof 24
Sort By:
NPJ Breast Cancer|July 13, 2024
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancerPeter A Fasching, Chunling Hu, Steven N Hart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on PrognosisPeter A Fasching, Siddhartha Yadav, Chunling Hu, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Breast Care (Basel, Switzerland)|July 12, 2021
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021Marc Thill, Michael Friedrich, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|July 12, 2021
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021Nina Ditsch, Cornelia Kolberg-Liedtke, Michael Friedrich, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2026
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 StudyMaggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Pageof 24

Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
NPJ Breast Cancer|July 13, 2024
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancerPeter A Fasching, Chunling Hu, Steven N Hart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2021
Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer -Association With Patient and Disease Characteristics and Effect on PrognosisPeter A Fasching, Siddhartha Yadav, Chunling Hu, et al.
International Journal of Cancer|March 23, 2019
Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patientsNaiba Nabieva, Lothar Häberle, Sara Y Brucker, et al.
Breast (Edinburgh, Scotland)|January 21, 2020
Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patientsC C Hack, L Häberle, S Y Brucker, et al.
Breast Care (Basel, Switzerland)|July 12, 2021
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021Marc Thill, Michael Friedrich, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|July 12, 2021
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021Nina Ditsch, Cornelia Kolberg-Liedtke, Michael Friedrich, et al.
Breast Cancer Research and Treatment|April 2, 2026
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trialManuel Hörner, Lara M Tretschock, Nelson John, et al.
Breast Cancer Research and Treatment|January 4, 2019
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancerMarius Wunderle, Jutta Pretscher, Sara Y Brucker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2026
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 StudyMaggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface, et al.
NPJ Breast Cancer|April 11, 2026
PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registryManuel Hörner, Andreas Hartkopf, Nelson John, et al.
Pageof 24